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Summary: A time-resolved immunofluorometric assay (TR-IFMA) was used for the measurement of glycated
C3. The very high sensitivity of this technique allowed the direct measurement of glycated and non-glycated
proteins (especially C3) in chromatography eluates. C3 glycation in vitro after incubation with 20 mmol/1
glucose was always less than 3.5% by day 5. As determined with the TR-IFMA, the means + standard
deviations of glycated C3 were 0.20% + 0.04 for non-diabetic subjects and 0.88% ± 0.06 for insulin-
dependent diabetic patients. The low percentages of glycated C3 in both our in vitro and in vivo studies show
that this protein is subject to only moderate rates of glycation.
Introduction
There is now evidence that plasmatic proteins show
high percentages of glycation in diabetic patients (1,
2). Various contradictory studies concerning the con-
sequences of this glycation on the functional proper-
ties of proteins especially those involved in immune
mechanisms have been published (3 — 6).
The C3 complement component, the "main element"
of the complementary system, is involved in many
immune mechanisms, especially the transport and the
elimination of circulating immune complexes (7—9).
Austin et al. (10) reported relatively high levels of C3
glycation in both healthy subjects and diabetic pa-
tients. These results are surprising, given the short
half-life of the protein (48 hours).
It is of interest to investigate the possible effect of C3
glycation on immune mechanisms involving this com-
ponent. Therefore, the objective of the present study
was to evaluate the time course of C3 complement
glycation in vitro and the percentages of glycated C3
in both healthy subjects and diabetic patients.
Prior to their assay, glycated and non-glycated frac-
tions of C3 complement must be separated by boron-
ate affinity chromatography. Because of the low con-
centration of C3 in the eluates, Austin et al. (10)
performed a preliminary concentration by lyophili-
zation, before measurement by immunoturbidimetry.
To avoid this concentration step, a very sensitive time-
resolved immunofluorometric assay (TR-IFMA) was
proposed. Its very high sensitivity was reported in a
previous study (11), and it was used in the present
study for the direct measurement of C3 in chroma-
tography eluates.
Materials and Methods
Study populat ion
Two groups of patients were studied:
The first group consisted of 30 non-diabetic healthy subjects
(15 men; 15 women; average age: 37 years, range 18 — 60), whose
glycaemia ranged from 4.5 to 6.5 mmol/1, and with no impair-
ment of post-absorption glycaemia.
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The second group consisted of 30 diabetic insulin-dependent
patients (15 men; 15 women; average age: 48 years; range: 20-
74) whose glycated haemoglobin ranged from 6.8 to 13.7%
(mean = 9.9, SD = 1.6). Blood samples were collected by
venipuncture in EDTA-containing tubes, and in evacuated
blood-collection tubes without anticoagulant. Plasma and sera
were immediatly centrifuged al 500 £ and stored at -20°C
until the assay.
Statist ical analysis
Percentages of each specific glycated protein (C3 complement,
albumin and IgG) were compared between the two groups using
the Mann & Whitney non-parametric test. Correlations between
parameters were studied with the Spearman rank correlation
test.
Separa t ion of glycated and non-glycated proteins
Proteins were separated into glycated and non-glycated frac-
tions by boronater affinity chromatography (Glyco-Gel™ An-
alytical Columns-Pierce, Rockford, IL) as previously described
(12 — 14), equilibrated with ammonium acetate 0.25 mol/1, mag-
nesium chloride 0.005 mol/1 buffer, pH 8. Non-glycated proteins
were eluted with 20.2 ml of the same buffer. Glycated proteins
were eluted with 3 ml of sodium citrate buffer 0.2 mol/1, pH
4.5.
Protocol of in v i t ro glycation
Pooled sera from non-diabetic patients (total C3 concentration
= 0.67 g/1) were immediately divided in 3 aliquots of 5 ml each
(A, B, C). Fraction A was incubated for up to five days at
37 °C in the presence of sodium-potassium phosphate buffer
0.05 mol/1, pH 7.5, NaN3 300 mg/1. Fractions B and C were
incubated with 66 mmol/1 sodium-potassium phosphate buffer,
pH 7.5, containing 1 g/1 NaN3 as preservative, and glucose (20
mmol/1 for A, 500 mmol/1 for B). Two ml of each fraction were
taken at day 0, 2, 3 and 5, and immediately dialysed against
NaCl 0.15 mol/1 for 24 hours at 4°C. Proteins were then
separated into glycated and non-glycated fractions as described
previously. Concentrations of glycated and non-glycated C3,
albumin and immunoglobulins (IgG) were determined.
Measurement of total C3 and glycated and non-
glycated C3 fractions with TR-IFMA
Concentrations of C3 in glycated and non-glycated fractions
were measured using TR-IFMA. This method was described
previously (11). Briefly, it includes the europium-labelling
(Kabi-Pharmacia, Uppsala, Sweden) of an antibody to human
C3c (Dako, Copenhagen, Denmark) and the immunoassay pro-
cedure. Polystyrene microtitre plates (Microwell™, Nunc Inc.,
Naperville, IL) were coated by adding 200 μΐ of unlabelled
antibody to C3c solution. The wells were then washed three
tiroes with 250 μΐ of a saturation solution (50 mmol/1 NaH2PO4
χ 2 H2O containing 60 g of sorbitol and 0.5 g of bovine serum
albumin per litre) per well to block non-specific binding sites.
After incubation of sera diluted to 10""3 and 10~2, glycated
eluates diluted to 10~2 and 10"1 and non-glycated eluates di-
luted to 10~3 and 10~2, then washing, the wells were incubated
with the conjugate. The amount of labelled antibody bound to
C3 was quantified by first dissociating europium from the
antibody with enhancement solution. The fluorescence of the
formed europium 2-naphthoyl-tri-fluoro-acetone acetate was
measured as counts per second in a time-resolved fluorometer
(Arcus™ 1230, Wallac Oy, Turku, Finland).
Other assays
HbA,c was measured using high performance liquid chroma-
tography (Diamat™, Biorad, Richmond, CA). Fructosamine
was measured using the colorimetric absorption of reduced
nitroblue tetrazolium (fructosamine test plus™, Roche, Bale,
Switzerland). Immune complexes were measured using the solid
phase Clq binding immunonephelometric assay (BNA™, Behr-
ing, Marburg, Germany). The glycated and non-glycated al-
bumin and IgG fractions were measured in the eluates using
immunonephelometric assay.
Results
In vitro glycation
The time course of the percentage glycation of C3,
albumin and IgG is presented in figure 1. Without
prior incubation of pooled sera with glucose, the
percentage of glycated C3 was very low, always lower
than 1%, and showed very little variation. Incubation
of pooled sera with 20 mmol/1 glucose resulted in a
very low percentage of glycated C3: 1.5 and 3.4% at
day 2 and day 5, respectively. However, with a solu-
tion of 500 mmol/1 glucose, the percentage of C3
glycation was relatively high (12.5%) at day 2 and
reached 63.3% at day 5. It was noteworthy that the
percentages of glycated albumin were close to,those
of glycated C3 after incubation with 20 mmol/1 glu-
100 r a
Fig. 1. Time course of glycation of C3 complement, albumin
and IgG following incubation of serum in vitro for
periods of 0 to 5 days in buffer containing
a) 20 mmol and . ·
b) 500 mmol of glucose per litre at pH 7.5
— ·— C3 complement, — o— albumin, — x— IgG
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cose (1.3 at day 2 and 2.6 at day 5), in contrast to
the percentages of glycated IgG which were already
high after incubation with 20 mmol/1 glucose (19%
at day 2 and 33% at day 5). It was noteworthy that
the percentage of glycated IgG was 83% at day 5
after incubation with 500 mmol/1 glucose.
In vivo study
Table 1 gives the means and standard deviations for
the percentages of glycated C3, other glycated quan-
tities, and the concentrations of total C3, and immune
complexes measured in each group.
Tab. 1. Comparison of means of immune complexes, C3 com-
plement, glycated C3 and other glycaled proteins be-
tween healthy subjects and diabetic patients
Immune complexes
(mg/1)
C3 complement
(mg/1)
Healthy
subjects
(n = 30)
x
a) ± SDb)
1.42 ± 0.71
607 ± 127
Diabetic
patients
(n = 30)
x
a) ± SDb)
1.63 ± 1.38
640 ± 105
Glycated fractions (%)
C3
IgG
Albumin
Fructosamine
(μηιοΐ/ΐ)
HbAlc (%)c)
0.20
6.01
0.87
214
4.85
±
±
±
±
±
0.04
1.25
0.15
25
0.30
0.88*
13.89*
3.37*
364*
9.69*
+
±
±
±
±
0.6
5.27
0.99
80
1.85
a) Mean values
b) Standard deviation
Statistical comparison between the mean of studied quantities
in healthy and patient groups (*p < 0.001); Mann & Whitney's
test
c) Fraction of haemoglobin
The percentages of glycated C3 were significantly
higher in diabetic patients than in healthy subjects
(p < 0.001) (0.88% and 0.20%, respectively). Nev-
ertheless, there was no significant difference between
groups for the concentrations of total C3 and immune
complexes.
The percentages of glycated C3 and HbAlc were sig-
nificantly correlated (p < 0.01). A lower correlation
was found between the percentages of glycated C3
and glycated albumin (p < 0.05). There was no sig-
nificant relationship between the percentages of gly-
cated C3 and those of glycated IgG and fructosamine
respectively.
Discussion
In view of the low concentrations of glycated C3, a
TR-IFMA was used in the present study. Its very high
sensitivity was described in a previous study (11). This
method allows the direct measurement of components
in chromatography eluates and therefore avoids the
preliminary step of concentration.
After incubation with 20 mmol/1 glucose, the per-
centage of glycated C3 was very low at day 2 and
was always less than 3.5% by day 5. The time course
of C3 glycation was close to that of albumin glycation.
The relatively high percentage of glycated IgG found
in the present study was also reported by Dolhofer-
Bliesener et al. (15). However, the high percentages
of glycated C3 (higher than 60% at day 5) found with
500 mmol/1 glucose were close to those found by
Austin et al. (10). Moreover, the percentages of gly-
cated albumin and IgG described in the present study
are in agreement with those reported by Austin et al.
(10).
The low percentage of glycated C3 observed in vitro
with 20 mmol/1 glucose was also found in in vivo
experiments, both in non-diabetic subjects and dia-
betic patients (0.20% and 0.88%, respectively). How-
ever, in comparison with non-diabetic subjects, the
percentage of glycated C3 increased significantly in
diabetic patients. Austin et al. (10) also reported such
a difference, although the percentages they found were
very different to ours (about ten times higher).
Such divergences between the two studies could be
perhaps explained by the prior step of lyophilization
used by Austin et al. (10).
The low percentages of glycated C3 found in the
present study appear more reasonable in view of the
half-life of this protein (48 hours). These lower per-
centages both in non-diabetic subjects and diabetic
patients show that the protein is subject to only mod-
erate rates of glycation. Moreover, there is enough
C3 in the organism to ensure that the entire comple-
ment system is functional. Therefore, it is reasonable
to assume that there was no alteration of complement
function.
Such an hypothesis is supported by results for IgG
glycation (5, 6). Morin et al. (5) found no impairment
of antigen-antibody binding after in vitro glycation
of non-human IgG with very high glucose concentra-
tions. Furthermore, no variation is observed in cell
agglutination, complement-mediated lymphocytotox-
icity reaction between human IgG before and after in
vitro glycation, even with very high glucose concen-
trations. Similar results were reported for eluates of
glycated and non-glycated IgG.
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No significant increase of immune complexes in dia-
betic patients was found in the present study in agree-
ment with Di Mario et al. (8, 9). There is no evidence
that the temporary increase of circulating immune
complexes near the time of diabetes diagnosis de-
scribed by some authors (7,17) is related to glycation.
This increase of the immune complexes is probably
due to other impairments of immune mechanisms.
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